Angiotensin AT
Animals
Calcium
/ metabolism
Corpus Striatum
/ metabolism
Cyclic AMP
/ metabolism
Dyskinesia, Drug-Induced
/ genetics
HEK293 Cells
Humans
Levodopa
Mice
Phosphorylation
Rats
Receptor, Angiotensin, Type 1
/ genetics
Receptor, Angiotensin, Type 2
/ genetics
Renin-Angiotensin System
/ physiology
Signal Transduction
/ physiology
Substantia Nigra
/ metabolism
Dyskinesia
G-protein-coupled receptor (GPCR)
Heteromer
Levodopa
Neuroinflammation
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
17 Aug 2020
17 Aug 2020
Historique:
received:
25
03
2020
accepted:
21
07
2020
entrez:
19
8
2020
pubmed:
19
8
2020
medline:
16
7
2021
Statut:
epublish
Résumé
The renin-angiotensin system (RAS) is altered in Parkinson's disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side effect. Angiotensin AT Immunocytochemistry was used to analyze the colocalization between angiotensin receptors; bioluminescence resonance energy transfer was used to detect AT We confirmed that AT The results indicate that boosting the action of neuroprotective AT
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
The renin-angiotensin system (RAS) is altered in Parkinson's disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side effect. Angiotensin AT
METHODS
METHODS
Immunocytochemistry was used to analyze the colocalization between angiotensin receptors; bioluminescence resonance energy transfer was used to detect AT
RESULTS
RESULTS
We confirmed that AT
CONCLUSION
CONCLUSIONS
The results indicate that boosting the action of neuroprotective AT
Identifiants
pubmed: 32807174
doi: 10.1186/s12974-020-01908-z
pii: 10.1186/s12974-020-01908-z
pmc: PMC7430099
doi:
Substances chimiques
Receptor, Angiotensin, Type 1
0
Receptor, Angiotensin, Type 2
0
Levodopa
46627O600J
Cyclic AMP
E0399OZS9N
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243Subventions
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : RTI2018-094204-B-I00
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : RTI2018-098830-B-I00
Références
J Neuroinflammation. 2017 Mar 16;14(1):54
pubmed: 28302135
Methods Mol Biol. 2013;963:147-69
pubmed: 23296610
Mov Disord. 2013 Sep;28(10):1337-42
pubmed: 23925977
Pflugers Arch. 2013 Jan;465(1):99-110
pubmed: 22949090
Exp Neurol. 2014 Nov;261:720-32
pubmed: 25160895
Nature. 2013 Jul 18;499(7458):295-300
pubmed: 23868258
Peptides. 2005 Aug;26(8):1401-9
pubmed: 16042980
Clin Sci (Lond). 2015 Jan;128(2):95-109
pubmed: 25052203
Expert Opin Investig Drugs. 2017 Oct;26(10):1163-1173
pubmed: 28836869
Glia. 2015 Mar;63(3):466-82
pubmed: 25377425
J Neural Transm Suppl. 2006;(70):9-15
pubmed: 17017502
Nat Chem Biol. 2009 Mar;5(3):131-4
pubmed: 19219011
Exp Neurol. 2014 Mar;253:180-91
pubmed: 24412491
J Neurochem. 2009 Apr;109(2):656-69
pubmed: 19245663
Circulation. 2003 Sep 30;108(13):1611-8
pubmed: 12963634
Oncotarget. 2018 Feb 6;9(17):13593-13611
pubmed: 29568380
Neurobiol Dis. 2008 Jul;31(1):58-73
pubmed: 18499466
Curr Hypertens Rep. 2018 May 1;20(5):41
pubmed: 29717388
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):487-498
pubmed: 29368003
Arch Psychiatr Nervenkr. 1964 Dec 2;206:367-81
pubmed: 14345318
Hypertension. 2017 Jun;69(6):1128-1135
pubmed: 28461604
Brain Behav Immun. 2018 Jan;67:139-151
pubmed: 28843453
PLoS One. 2017 Jul 3;12(7):e0180738
pubmed: 28671997
Mol Neurobiol. 2018 Jun;55(6):5282-5298
pubmed: 28884281
ScientificWorldJournal. 2009 Mar 31;9:229-35
pubmed: 19347234
Nature. 2000 Sep 7;407(6800):94-8
pubmed: 10993080
Neurobiol Dis. 2002 Jul;10(2):165-86
pubmed: 12127155
PLoS One. 2014 Jun 09;9(6):e98961
pubmed: 24910980
Regul Pept. 2007 Jun 7;141(1-3):159-67
pubmed: 17320985
J Neurosci. 2003 Dec 3;23(35):11136-41
pubmed: 14657172
Sci Rep. 2017 Nov 16;7(1):15717
pubmed: 29146920
Brain Struct Funct. 2013 Mar;218(2):373-88
pubmed: 22407459
Front Aging Neurosci. 2017 May 03;9:129
pubmed: 28515690
Brain. 2000 Jul;123 ( Pt 7):1365-79
pubmed: 10869049
Mov Disord. 2004 Sep;19(9):997-1005
pubmed: 15372588
EMBO J. 2011 May 03;30(12):2350-63
pubmed: 21540834
Neuroimage. 2012 May 15;61(1):228-39
pubmed: 22406356
J Biol Chem. 2013 Jun 28;288(26):18872-84
pubmed: 23661707
Neurotherapeutics. 2018 Oct;15(4):1063-1081
pubmed: 29987762
J Neuropathol Exp Neurol. 2010 Nov;69(11):1130-42
pubmed: 20940627
J Neurosci. 2001 Apr 15;21(8):2889-96
pubmed: 11306640
Mol Neurobiol. 2019 Apr;56(4):3005-3023
pubmed: 30076526
PLoS One. 2014 Apr 21;9(4):e95762
pubmed: 24752645
Mol Cell Neurosci. 2015 Mar;65:58-67
pubmed: 25724109
Eur J Neurosci. 2002 Jan;15(1):120-32
pubmed: 11860512
Cell Signal. 2011 Nov;23(11):1767-76
pubmed: 21740964
Hypertension. 2006 Aug;48(2):316-22
pubmed: 16754789
Nat Med. 2001 Sep;7(9):1003-9
pubmed: 11533702
Hypertension. 2016 Oct;68(4):1039-48
pubmed: 27550920
Mol Neurodegener. 2007 Jan 15;2:1
pubmed: 17224059
Brain Res. 2015 Jan 12;1594:27-35
pubmed: 25451117
Br J Pharmacol. 2013 Mar;168(5):1104-17
pubmed: 22935142
Neurochem Res. 2016 Mar;41(3):523-33
pubmed: 26177578
Clin Sci (Lond). 2015 Feb;128(4):227-34
pubmed: 25328009
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Front Aging Neurosci. 2017 Nov 03;9:365
pubmed: 29163145
Brain Struct Funct. 2017 Aug;222(6):2559-2571
pubmed: 28161727
Adv Neurol. 1997;73:229-38
pubmed: 8959217
Glia. 2003 Dec;44(3):183-9
pubmed: 14603460
Am J Physiol Renal Physiol. 2012 Apr 1;302(7):F875-83
pubmed: 22218590
Peptides. 2014 Jul;57:101-8
pubmed: 24819472
Mol Neurobiol. 2015 Dec;52(3):1408-1420
pubmed: 25344317
Biomol Concepts. 2018 Dec 26;9(1):143-154
pubmed: 30864350
Auton Autacoid Pharmacol. 2010 Jul;30(3):167-72
pubmed: 20102360